Effects of Xanthohumol on Metabolic Syndrome Progression

Overview

A huge body of scientific evidence has suggested that xanthohumol (XAN) consumption, a polyphenol present in beer, has a positive effect on energy metabolism. This compound is known for its antioxidant, anti-inflammatory and anti-cancer properties which confer potential to be used as a food supplement. Nevertheless, XAN lipophilic properties prevent the extensive use of this molecule as a functional food compound. The company TA-XAN S.A.M. (Wiesbaden, Germany) has patented a method to overcome this solubility problem. So, the main aim of this study is to evaluate the effects of XAN consumption on metabolic syndrome progression in individuals recently diagnosed.

Full Title of Study: “Effects of Xanthohumol on Metabolic Syndrome Progression (XAN4Health)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2018

Interventions

  • Dietary Supplement: XAN
    • Daily intake of a sachet containing 12 mg of XAN
  • Dietary Supplement: Placebo
    • Daily intake of a sachet containing excipient

Arms, Groups and Cohorts

  • Experimental: XAN
    • XAN (1 sachet of 12 mg/day)
  • Placebo Comparator: Placebo
    • Placebo (1 sachet with excipient)

Clinical Trial Outcome Measures

Primary Measures

  • Glycated hemoglobin (HbA1c)
    • Time Frame: Change from baseline of HbA1c at 3 months
  • Comet assay
    • Time Frame: Change from baseline of DNA damage at 3 months

Secondary Measures

  • HDL-cholesterol
    • Time Frame: Change from baseline of HDL-cholesterol at 3 months
  • LDL-cholesterol
    • Time Frame: Change from baseline of LDL-cholesterol at 3 months
  • Triglycerides
    • Time Frame: Change from baseline of triglycerides at 3 months
  • Total-cholesterol
    • Time Frame: Change from baseline of total-cholesterol at 3 months
  • Waist circumference
    • Time Frame: Change from baseline of waist circumference at 3 months
  • Body weight
    • Time Frame: Change from baseline of body weight at 3 months
  • Body composition
    • Time Frame: Change from baseline of body composition at 3 months
  • Blood pressure
    • Time Frame: Change from baseline of blood pressure at 3 months
  • Heart rate
    • Time Frame: Change from baseline of heart rate at 3 months
  • ApoB
    • Time Frame: Change from baseline of ApoB at 3 months
  • ApoA1
    • Time Frame: Change from baseline of ApoA1 at 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • Men and women, 25-65 years of age; – Criteria for metabolic syndrome according to the 2005 revised NCEP ATP III guidelines: – HDL-C < 40 mg/dL ♂ and < 50 mg/dL ♀; – Triglycerides ≥ 150 mg/dL; – Blood pressure ≥ 130/85 mmHg; – Fasting plasma glucose ≥ 100 mg/dL; – Waist circumference ≥ 102 cm ♂ and ≥ 88 cm ♀; – HbA1c 5.8/6.0-6.4; – Nonsmokers or no other tobacco use in the last 3 months; – Willing to stop taking regular supplements including antioxidants for 2 weeks prior to study entry through conclusion of study; – Willing to stop consumption of beer for 2 weeks prior to study entry through conclusion of study; – Must be able to provide informed consent; – Blood screen tests [comprehensive metabolic panel (CMP), and lipid profile] within normal limits or if outside normal limits, approved for participation at the discretion of the study physician. Exclusion Criteria:

  • Have a significant acute or chronic coexisting illness, such as cardiovascular disease, chronic kidney or liver disease, gastrointestinal disorder, endocrine disorder, immunological disorder, metabolic disease, cancer, chemotherapy history, gluten intolerance, eating disorders, depression or any psychiatric condition, diabetes, or any condition which contraindicates entry in the study, according to the investigators' judgment; – Currently taking prescription drugs other than oral contraceptives (over-the-counter medications are allowed upon review and discretion of the study physician); – Consumption of more than the recommended alcohol guidelines (> 1 drink/day ♀ and > 2 drinks/day ♂); – Consumption of high levels of beer; – Pregnancy (as confirmed by urine pregnancy test) or planning to become pregnant before completing the study; – Breastfeeding; – Under UV therapy (e.g. psoriasis treatment), using UV tanning beds and unprotected sun exposure greater than 1 hour/day; – Engaging in vigorous exercise more than 6 hours/week; – Participation in other dietary study in the past 3 months; – Had surgery in the last 3 months; – Post-menopausal status.

Gender Eligibility: All

Minimum Age: 25 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Universidade do Porto
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Raquel Soares, PhD, Principal Investigator, Medical Faculty of University of Porto
  • Overall Contact(s)
    • Raquel Soares, PhD, (+351)225513624, raqsoa@med.up.pt

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.